Evidence map›Paper›PMID 40505002›Full record

ArticleDiabetes2025

Cannabinoid Receptor 2 Agonism Demonstrates Therapeutic Potential in Experimental Models of Relevance to Diabetic Retinopathy.

Cayla D Ontko, Taylor E Smith, Amy K Stark, Juliana C Olson, Isabelle M Newkirk, Ariana L Jackson, Gary W McCollum, John S Penn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cayla D OntkoDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN.ORCID 0000-0001-6771-6108
Taylor E SmithDepartment of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN.
Amy K StarkDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN.
Juliana C OlsonDepartment of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN.
Isabelle M NewkirkDepartment of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN.
Ariana L JacksonDepartment of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN.
Gary W McCollumDepartment of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, TN.
John S PennDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
RETINOPATHY OF PREMATURITY--UNDERSTAND ITS PATHOGENESISR01EY007533 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENN, JOHN S. · 1993 to 2018
$7.0M
Training in Vision ResearchT32EY007135 · NEI · VANDERBILT UNIVERSITY · PI GEOFFREY F WOODMAN · 1994 to 2026
$5.8M
In Vivo Molecular Imaging of the RetinaR01EY023397 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENN, JOHN S., UDDIN, MD IMAM · 2013 to 2022
$3.6M
Training Program in Quantitative Ocular GenomicsT32EY021453 · NEI · VANDERBILT UNIVERSITY · PI BRANTLEY, MILAM A, COX, NANCY J · 2011 to 2020
$1.4M
Confocal Microscope for Live Embryo Imaging in a Shared Resource FacilityS10RR027396 · NCRR · VANDERBILT UNIVERSITY · PI PRINCE, LAWRENCE S · 2010 to 2010
$460k
Knights Templar Eye FoundationMildred Almen Reeves FoundationNCI NIH HHS P30 CA068485NCRR NIH HHS S10 RR027396NEI NIH HHS P30 EY008126NEI NIH HHS R01 EY007533NEI NIH HHS R01 EY023397NEI NIH HHS T32 EY007135NEI NIH HHS T32 EY021453NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIH HHS R01 EY007533NIH HHS R01 EY023397NIH HHS T32 EY007135NIH HHS T32 EY021453Research to Prevent Blindness, Inc
6 · The paper itself

Abstract

article highlightsAn effective treatment strategy for early-stage diabetic retinopathy (DR) could delay or prevent disease progression and limit or eliminate irreparable retinal damage and vision loss associated with progression to later stages of DR. Cannabinoid receptor 2 (CB2) activation strategies may provide a promising therapeutic approach to address the chronic retinal inflammation that encourages DR progression. CB2 activation therapeutically addresses leukocyte binding in human retinal microvascular endothelial cells and retinal leukostasis in diabetic mice, presumably by inhibiting nuclear factor κB-dependent transcription of adhesion molecules VCAM-1 and ICAM-1. CB2 agonism constitutes a rational therapeutic approach for clinical application to patients with early-stage DR.

Indexed as

Diabetic RetinopathyReceptor, Cannabinoid, CB2AnimalsDiabetes Mellitus, ExperimentalDisease Models, AnimalEndothelial CellsHumansIntercellular Adhesion Molecule-1MiceRetinaVascular Cell Adhesion Molecule-1Intercellular Adhesion Molecule-1Receptor, Cannabinoid, CB2Vascular Cell Adhesion Molecule-1

Identifiers

PMID40505002
PMCPMC12365422

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.